tbuckley/cabot-search huggingface dataset:
Detection of IgG and IgE reactivity to BP180 using the ISAC<sup>®</sup>microarray system
Authors: D. Pomponi, G. Di Zenzo, D. Zennaro, V. Calabresi, R. Eming, S. Zuzzi, M.L. Bernardi, E. Scala, A. Mari
Journal: British Journal of Dermatology (2012)

Journal Article Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system Get access D. Pomponi, D. Pomponi Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Di Zenzo, G. Di Zenzo Molecular and Cell Biology Laboratory, IDI‐IRCCS, Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar D. Zennaro, D. Zennaro Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar V. Calabresi, V. Calabresi Molecular and Cell Biology Laboratory, IDI‐IRCCS, Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar R. Eming, R. Eming Department of Dermatology and Allergology, Philipps University, Marburg, Germany Search for other works by this author on: Oxford Academic Google Scholar S. Zuzzi, S. Zuzzi Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar M.L. Bernardi, M.L. Bernardi Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar E. Scala, E. Scala Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Search for other works by this author on: Oxford Academic Google Scholar A. Mari A. Mari Center for Molecular Allergology, IDI‐IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy Adriano Mari. E‐mail: adriano.mari@idi.it Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 168, Issue 6, 1 June 2013, Pages 1205–1214, https://doi.org/10.1111/bjd.12161 Published: 01 June 2013 Article history Accepted: 26 November 2012 Published: 01 June 2013
Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation
Authors: Stavros Apostolakis, Deirdre A. Lane, Yutao Guo, Harry Buller, Gregory Y.H. Lip
Journal: Journal of the American College of Cardiology (2012)
Abstract 17459: Drug Eluting Balloon Angioplasty is a Safe Treatment Option for In-stent Restenosis: Meta-analysis of Current Evidence
Authors: Sainath Gaddam, Bhavi Pandya, Mustafain Meghani, Vratika Agarwal, Armaghan Soomro, Srinivas Duvvuri, James Lafferty, Roman Royzman, Ruben Kandov
Journal: Circulation (2014)

Introduction: Drug eluting balloons (DEB) were recently approved by FDA for peripheral artery interventions only. For coronary in-stent restenosis (ISR), the ACC/AHA/SCAI 2011 PCI guidelines have no recommendations on role for DEB. While ESC/EACTS 2010 PCI guidelines, have level IIa recommendation for DEB for ISR after a bare metal stent. The drug delivery kinetics with DEB allows shorter duration of dual anti-platelet therapy and has a potential role in ballooning side branches of a bifurcating lesion after stenting. Aim: To compare safety and efficacy of DEB angioplasty vs. plain old balloon angioplasty (BA) or drug eluting stent (DES) for treating coronary ISR. Methods and Results: A thorough search was performed on Pubmed, Embace and Google scholar databases for randomized control trials (RCT) comparing DEB vs. BA or DES for ISR. We compared target lesion revascularization (TLR) and MACE events for these groups. We also pooled data from registries and observation studies on DEB for outcome analysis. Total number of patients with DEB’s in our study was 3465, with 693 DEB’s in 8 RCT’s. Mean follow up period was 11 months. Pooled analysis showed significant benefit for DEB compared to plain old BA, for events of target lesion revascularization (OR= 0.25, p&lt;0.0001), and death (OR=0.31, p&lt;0.0001). Comparing DEB to DES, there was no statistical difference in outcomes comparing TLR (OR=1.4, p=0.14), MI or death (OR=0.65, p=0.39). Cumulative incidence of target lesion revascularization (TLR) with DEB was 6.7%. Conclusions: For coronary ISR, drug eluting balloon angioplasty is superior to plain old balloon angioplasty in terms of safety and outcomes. However, comparing drug eluting balloons vs. drug eluting stents in ISR, the outcomes are comparable and will need larger studies powered to make definitive recommendation.
Age might confound the impact of the transmembrane 6 superfamily member 2 E167K polymorphism on hepatic fibrosis in hepatitis C virus–infected patients
Authors: Zhengtao Liu, Tianchi Chen, Yan Wang, Min Zhang, Lin Zhou, Shusen Zheng
Journal: Hepatology (2015)

Financial support for this work was received from the National S&T Major Project (no. 2012ZX10002017) and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (grant no.: 81421062). Potential conflict of interest: Nothing to report. Author names in bold designate shared co‐first authorship To the Editor: We read with great interest the article by Milano et al.1 published in Hepatology. The researchers discussed the impact of transmembrane 6 superfamily member 2 (TM6SF2) as a "hot" single‐nucleotide polymorphism on the degree of steatosis and severity of histological damage in two independent cohorts of European hospital‐based patients infected with hepatitis C virus (HCV). However, some results involving the validation cohort are questionable. First, carriers with variant TM6SF2 were 2 years younger than carriers with wild genotype according to the Supporting Information, and age also had a positive role in inducing the hepatic fibrosis process. Thus, collinearity existed between age and the TM6SF2 variant based on a multicovariate analysis of fibrosis in the validation cohort. Part of the contribution of the TM6SF2 E167K polymorphism on hepatic fibrosis in the validation cohort was underestimated with respect to the uneven age distribution of different polymorphisms. In addition, obesity (as indicated by body mass index or waist circumstance) is an important metabolic phenotype that exerts significant influence on hepatic lesions in patients infected with HCV or non‐HCV.2 Indeed, dismissing an adjustment for obesity in the multicovariate analysis also caused inevitable bias in evaluating risk for the TM6SF2 variant. Therefore, we suggest that specific risk evaluation for the TM6SF2 variant on hepatic fibrosis in the validation cohort1 should be considered with caution in a nonrigorous comparison given the uneven age distribution and absence of an obesity correction.
Abstract 4122: Anti-cancer activity of rosemary extract in colon cancer cells: Involvement of Nrf2 and ERK pathways
Authors: Miao Yan, Gongbo Li, Sakina M. Patiwala, Emily Householter, Jeremy J. Johnson
Journal: Cancer Research (2014)

Abstract Background: The Mediterranean herb rosemary has been used for culinary purposes and for their medicinal properties for millennia. Rosemary and its polyphenolic diterpenes (carnosol and carnosic acid) are known to possess anti-oxidant activity that may be beneficial for cancer control. Colorectal cancer is the second leading cause of death from cancer in the United States. Nutrition, particularly intake of vegetables and certain plant components, has been reported to have a major role in colon cancer risk reduction. In our current study, we investigated the anticancer effects of rosemary extract and its two main active ingredients carnosol and carnosic acid on colon cancer cell lines to understand the mechanism. Next, we evaluated the anti-cancer activity of rosemary extract in a nude mice model. Methods: Two human colon cancer cell lines, HCT116 and SW480, were treated with rosemary extract, carnosol or carnosic acid. MTT, TUNEL and ELISA were used to evaluate cell viability and apoptosis. Western blot and immunofluorescence were used to detect proteins involved in apoptosis. We also evaluated the anti-cancer activity of rosemary extract in nude mouse inoculated with HCT116 cells. Results: Rosemary extract, carnosol and carnosic acid, increased apoptosis, decreased viability in colon cancer cell lines. Rosemary extract, carnosol and carnosic acid significantly upregulated the expression of Nrf2 and ERK. Rosemary extract also effectively suppressed tumor growth in a xenograft tumor model without affecting body weight. Conclusions: Rosemary extract inhibits colon cancer cell growth in a xenograft mouse model without observable toxicity. Furthermore, rosemary extract, carnosol and carnosic acid induce the expression of Nrf2 and ERK pathways in colon cancer cells, suggesting further research is needed to evaluate its potential as an anti-cancer and/or chemoprevention agent. Citation Format: Miao Yan, Gongbo Li, Sakina M. Patiwala, Emily Householter, Jeremy J. Johnson. Anti-cancer activity of rosemary extract in colon cancer cells: Involvement of Nrf2 and ERK pathways. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4122. doi:10.1158/1538-7445.AM2014-4122
Abstract A44: S100A4 drives the invasive potential of non-small cell lung cancer cells and is targeted by FDA approved drugs
Authors: Min Chen, Rachel Stewart, Teresa Knifley, Brittany L. Carpenter
Journal: Clinical Cancer Research (2015)

Abstract The metastatic nature of advanced non-small cell lung cancer (NSCLC), often associated with therapeutic resistance, accounts for the majority of cancer death with the 5-year survival rate less than 10%. This dismal outcome will remain the same until we gain better understanding of the crucial drivers of the metastatic process and gain the power to effectively target them. S100A4 is a tumor metastasis associated protein and an epithelial to mesenchymal transition (EMT) marker. S100A4 contributes to several hallmarks of cancer such as anti-apoptosis, proliferation and therapeutic resistance, and has been implicated in the progression of different types of cancer, including breast, colon and pancreatic cancer. However, the impact of S100A4 signaling in lung cancer progression and its potential use as a target for therapy in lung cancer has not been properly explored. Here, by using established lung cancer cell lines, we demonstrate that S100A4 is upregulated in a subset of lung cancer cell lines both at the mRNA and protein levels. We further found that inhibition of S100A4 by shRNA in A549 and H460 lung cancer cell lines reduced cell proliferation and decreased 3D invasive growth, while exogenous overexpression of S100A4 in H1299 cells increased invasive potential. Interestingly, we showed that Niclosamide, an FDA-approved anti-tapeworm agent, suppressed S100A4 expression in A549 and H358 cells and led to decreased cell proliferation, invasion and invasive growth. Similarly, we found that a CDC25 inhibitor, NSC95397, disrupts the interaction of S100A4 and non-muscle myosin IIA and also decreased A549 cell invasion. Collectively, these data highlight the importance of S100A4 in lung cancer invasion and metastasis and provide the rationale for targeting S100A4 as a potential agent to combat lung cancer. Citation Format: Min Chen, Rachel Stewart, Teresa Knifley, Brittany L. Carpenter. S100A4 drives the invasive potential of non-small cell lung cancer cells and is targeted by FDA approved drugs. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr A44.
THE INDIVIDUALITY OF THE AMERICAN COLLEGE OF PHYSICIANS
Authors: R FITZ
Journal: Annals of Internal Medicine (1950)

Article1 June 1950THE INDIVIDUALITY OF THE AMERICAN COLLEGE OF PHYSICIANSREGINALD FITZ, F.A.C.P.REGINALD FITZ, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-6-1015 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe by-laws of the College stipulate that the President shall deliver an address at each annual Convocation. In fulfilling this obligation my predecessors in office have chosen for consideration a wide range of subjects; in early days, and chiefly for the benefit of new Fellows, the President often limited his remarks to a review of the immediate affairs of the College. This is a precedent which I propose to revive on this occasion.Many years ago Dr. Harvey Cushing read a delightful paper at an Ether Day celebration in the Massachusetts General Hospital. He began by saying that as human... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*President's address, Thirty-First Annual Session, American College of Physicians, Boston, Mass., April 19, 1950. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1950Volume 32, Issue 6Page: 1015-1018 ePublished: 1 December 2008 Issue Published: 1 June 1950 Copyright & PermissionsCopyright, 1950, by The American College of PhysiciansPDF downloadLoading ...
Abstract 2772: Ceramide analog sensitizes breast cancer cells to Fas-mediated apoptosis to suppress spontaneous lung metastasis
Authors: Xia Li, Amy V. Paschall, Aiping Bai, Jacek Bielawski, Alicja Bielawska, Kebin Liu
Journal: Cancer Research (2014)

Abstract Fas is a member of the TNF death receptor superfamily. Despite other “non-apoptotic” cellular responses emanating from its signaling, the major and best known function of Fas is apoptosis. To avoid apoptosis, cancer cells, including breast cancer cells, tend to down-regulate Fas expression or alter the expression of key mediators of the Fas-mediated apoptosis signaling pathway to advance the disease. Therefore, therapeutic intervention of tumor cell resistance to Fas-mediated apoptosis potentially represents an effective approach to render tumor cell sensitivity to FasL+ cytotoxic T lymphocytes (CTL) of the host immunosurveillance system or to CTL-based adoptive cancer immunotherapy to suppress tumor progression. We report here that sublethal doses of ceramide analog LCL85 effectively overcome metastatic human breast cancer cells to FasL-induced apoptosis in vitro. Although it has been shown that ceramide targets the Bcl-2 family proteins to induce tumor cell apoptosis, we observed that LCL85 does not alter Bak, Bax, Bcl-2 and Bcl-xL protein levels in metastatic human breast cancer cells. Instead, we determined that LCL85 dramatically decreased cIAP1 and xIAP protein levels in the metastatic human breast cancer cells. Consistent with its apoptosis sensitization activity, subtoxic doses of LCL85 suppressed primary breast cancer growth. More importantly, subtoxic doses of LCL85 effectively suppressed spontaneous lung metastasis in an orthotopic breast cancer mouse model. Furthermore, LCL85 exhibited no significant liver toxicity in vivo at the effective doses. Our data thus suggest that LCL85, although effective as a single agent in suppression of tumor development at high doses, might be more valuable if used at a sublethal dose as a sensitizer for enhancing the efficacy of FasL-based cancer therapy, particularly CTL-based cancer immunotherapy. Note: This abstract was not presented at the meeting. Citation Format: Xia Li, Amy V. Paschall, Aiping Bai, Jacek Bielawski, Alicja Bielawska, Kebin Liu. Ceramide analog sensitizes breast cancer cells to Fas-mediated apoptosis to suppress spontaneous lung metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2772. doi:10.1158/1538-7445.AM2014-2772
Endothelial Progenitor Cells Are Rapidly Recruited to Myocardium and Mediate Protective Effect of Ischemic Preconditioning via “Imported” Nitric Oxide Synthase Activity
Authors: Masaaki Ii, Hiromi Nishimura, Atsushi Iwakura, Andrea Wecker, Elizabeth Eaton, Takayuki Asahara, Douglas W. Losordo
Journal: Circulation (2005)

Background— The function of bone marrow–derived endothelial progenitor cells (EPCs) in repair of ischemic tissue has been the subject of intense scrutiny, and the capacity of these cells to contribute significantly to new blood vessels remains controversial. The possibility that EPCs could act as reservoirs of cytokines has been implied by several observations; however, a specific role for cytokine delivery has not been identified. Methods and Results— We performed a series of experiments that revealed the rapid recruitment of EPCs to the myocardium by very short periods of ischemia, so-called ischemic preconditioning. The recruited EPCs express an array of potentially cardioprotective cytokines including nitric oxide synthase isoforms. Bone marrow transplantation studies, using donor marrow null for nitric oxide synthase isoforms, revealed that both endothelial and inducible nitric oxide synthase derived from bone marrow cells play essential roles in the cardioprotective effect that normally occurs after ischemic preconditioning. Conclusions— These findings provide novel insights about the role of bone marrow–derived cells in ischemic preconditioning and also reveal that distinct mechanisms regulate recovery after ischemia-reperfusion and chronic ischemic injury.
Abstract 19309: Feasibility and Angiographic Six-Month Follow-up of Fractional Flow Reserve - Guided Coronary Angioplasty Using Paclitaxel-Coated Balloons Without Stent Implantation (OCTOPUS II Study, NCT 02120859)
Authors: Tudor C Poerner, Sylvia Otto, Corinna Duderstadt, Juan Luis Guttiérrez-Chico, Hans R Figulla
Journal: Circulation (2014)

Introduction: Percutaneous coronary interventions (PCI) with drug-eluting balloons (DEB) might be a promising trade-off between balloon angioplasty (POBA) and drug-eluting stents, since DEB effectively inhibit neointimal proliferation and also limit duration of dual antiplatelet therapy.

Hypothesis: We investigated the safety and feasibility of fractional flow reserve (FFR) - guided use of the paclitaxel-eluting Sequent Please™ DEB without stenting for elective PCI of de novo lesions.

Methods: In 46 consecutive patients (54 lesions) with stable symptomatic coronary artery disease (CAD) a FFR-guided POBA was performed. In case of a sufficient POBA result with residual stenosis   0.8 and no flow-limiting dissection, another dilatation of the target lesion was carried out using the DEB. Quantitative coronary angiography (QCA) was attempted before and after the index procedure and at 6-month follow-up (f/u), when the late lumen loss (LLL) and net luminal gain (NLG) were calculated.

Results: The DEB-only concept could be applied to 43 patients (51 lesions), while 3 patients (3 lesions) needed provisional stenting. Invasive f/u was completed in 41 patients (47 lesions) (Fig.1). At the stenotic site, the lumen showed a trend towards progressive increase at f/u without aneurysm formation or restenosis after DEB-only treatment (Fig. 2).

Conclusions: The concept of FFR-guided DEB-only PCI of de novo lesions in stable CAD appeared safe and feasible and allowed to stop clopidogrel after 4 weeks. The antiproliferative effects of paclitaxel induce persistent vessel remodeling leading to late luminal gain at 6-month f/u after DEB angioplasty without stent implantation.

   ![][1]    ![][2]  [1]: /embed/graphic-1.gif
 [2]: /embed/graphic-2.gif
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
Authors: H Kitayama, Y Kanakura, T Furitsu, T Tsujimura, K Oritani, H Ikeda, H Sugahara, H Mitsui, Y Kanayama, Y Kitamura
Journal: Blood (1995)
A call to renew
Authors: L. H. Clever
Journal: BMJ (1999)

See also p 1633 

Why do so many physicians wallow in woe? Why do so few resist imposed yet ill advised policies, regulations, and practices? Why is there reluctance to band together with each other and patients to make suggestions and take action? Physicians list several reasons. Some find that the pleasures of the practice of medicine outweigh the problems, so they choose to disregard the problems. Others report that clinical ambiguities can lead to professional paralysis. A recent issue of the BMJ , for example, highlighted the shortcomings of available science: we do not know how to prevent deaths caused by mentally ill people,1 the best surgeons to operate on patients with pituitary tumours,2 or the explanation of chronic pelvic pain in men.3 Minerva reported the difficulty of performing much vaunted meta-analyses.4 Since uncertainties far outnumber certainties in science, medicine, and life, slow brownian motion—keeping a low profile—seems less upsetting and risky than thrusting forward.

Other reasons given for moaning instead of moving ahead include: “We were brainwashed during training,” “Authorities don't respond, so why bother?” “Our …
Abstract 2892: Vaccination with a therapeutic cancer vaccine containing prostate specific antigen and the biological adjuvants IL-2 and GM-CSF results in reduced serum PSA in prostate cancer patients
Authors: Jonathan F. Head, Robert L. Elliott
Journal: Cancer Research (2014)

Abstract In 1997 we initiated a phase I/II clinical trial of a therapeutic prostate cancer vaccine. We have enrolled 12 biopsy confirmed prostate cancer patients in this study and 11 finished the initial course of 6 intradermal vaccinations containing prostate specific antigen (50 μg) and biological adjuvants (IL-2, 20,000 units, and GM-CSF, 16.7 μg) at 0, 1, 2, 6, 10 and 14 weeks. During this study the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy). One of the 12 patient's PSA rose from 7.6 to 13.7 after the fourth vaccination and he (patient #8) withdrew from the study to seek other therapy. In the remaining 11 prostate cancer patients serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. There was a decrease in the PSA levels in 8 of 12 of the prostate cancer patients after 6 vaccinations. One of the patients (patient #3), whose PSA had dropped from 6.8 to 6.4 and had previously received radiotherapy (the only patient previously treated), elected to withdraw from the study and underwent radical prostatectomy. Nine of the original 12 patients have received monthly 3 intradermal IL-2 injections (11 million units) alternated with 3 further vaccinations for the 6 months following the initial vaccinations, and 8 patients have been followed from 18 to 92 months. The mean PSA values for the 8 patients still being followed without additional therapy were 5.8 initially, decreasing to 4.1 after 6 vaccines, 3.7 after 12 vaccines and is 4.7 after a mean follow-up of 49 months (median follow-up of 45.5 months). These promising results have led to the creation of the U.S. Navy Cancer Vaccine Program with a Phase I clinical trial at the Veterans Administration Medical Center San Diego/UCSD Medical School. Citation Format: Jonathan F. Head, Robert L. Elliott. Vaccination with a therapeutic cancer vaccine containing prostate specific antigen and the biological adjuvants IL-2 and GM-CSF results in reduced serum PSA in prostate cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2892. doi:10.1158/1538-7445.AM2014-2892
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas
Authors: R.L. Poorter, P.J.M. Bakker, M.T. Huizing, C.W. Taat, R.C. Rietbroek, D.J. Gouma, E.A.J. Rauws, C.H.N. Veenhof
Journal: Annals of Oncology (1995)